FindTrial
Sign In

Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes

BIOLOGICAL2 trials

Sponsors

Fred Hutchinson Cancer Center

Conditions

Acute Myeloid LeukemiaAdvanced Pleural Malignant MesotheliomaBlasts Under 5 Percent of Bone Marrow Nucleated CellsEBV-Positive Neoplastic Cells PresentElevated WT1HLA-A*0201 Positive Cells PresentRecurrent Non-Small Cell Lung CarcinomaRecurrent Pleural Malignant Mesothelioma

Phase 1

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
TerminatedNCT02408016
Fred Hutchinson Cancer CenterAdvanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma +8
Start: 2015-05-22End: 2020-06-30Updated: 2021-09-13
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
TerminatedNCT02770820
Fred Hutchinson Cancer CenterAcute Myeloid Leukemia, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, EBV-Positive Neoplastic Cells Present +2
Start: 2017-11-06End: 2020-06-01Updated: 2021-10-29

Related Papers

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
Journal for ImmunoTherapy of Cancer2021-08-016 citations